Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 18 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 11 |
NetGPI | no | yes: 0, no: 11 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005930 | axoneme | 2 | 1 |
GO:0110165 | cellular anatomical entity | 1 | 4 |
GO:0005929 | cilium | 4 | 3 |
GO:0031514 | motile cilium | 5 | 3 |
GO:0042995 | cell projection | 2 | 3 |
GO:0043226 | organelle | 2 | 3 |
GO:0043227 | membrane-bounded organelle | 3 | 3 |
GO:0120025 | plasma membrane bounded cell projection | 3 | 3 |
Related structures:
AlphaFold database: A4HNW4
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 238 | 242 | PF00656 | 0.491 |
CLV_NRD_NRD_1 | 284 | 286 | PF00675 | 0.628 |
CLV_PCSK_KEX2_1 | 218 | 220 | PF00082 | 0.569 |
CLV_PCSK_KEX2_1 | 284 | 286 | PF00082 | 0.614 |
CLV_PCSK_PC1ET2_1 | 218 | 220 | PF00082 | 0.434 |
CLV_PCSK_PC1ET2_1 | 284 | 286 | PF00082 | 0.630 |
DEG_APCC_DBOX_1 | 232 | 240 | PF00400 | 0.449 |
DOC_MAPK_gen_1 | 245 | 253 | PF00069 | 0.350 |
DOC_MAPK_MEF2A_6 | 48 | 57 | PF00069 | 0.517 |
DOC_USP7_MATH_1 | 51 | 55 | PF00917 | 0.339 |
DOC_USP7_MATH_1 | 67 | 71 | PF00917 | 0.413 |
DOC_USP7_UBL2_3 | 280 | 284 | PF12436 | 0.591 |
DOC_WW_Pin1_4 | 70 | 75 | PF00397 | 0.376 |
LIG_14-3-3_CanoR_1 | 111 | 115 | PF00244 | 0.297 |
LIG_14-3-3_CanoR_1 | 116 | 126 | PF00244 | 0.202 |
LIG_14-3-3_CanoR_1 | 194 | 199 | PF00244 | 0.556 |
LIG_14-3-3_CanoR_1 | 98 | 103 | PF00244 | 0.345 |
LIG_Actin_WH2_2 | 145 | 162 | PF00022 | 0.449 |
LIG_Actin_WH2_2 | 15 | 30 | PF00022 | 0.476 |
LIG_BIR_II_1 | 1 | 5 | PF00653 | 0.472 |
LIG_DLG_GKlike_1 | 98 | 105 | PF00625 | 0.413 |
LIG_eIF4E_1 | 60 | 66 | PF01652 | 0.449 |
LIG_FHA_1 | 159 | 165 | PF00498 | 0.614 |
LIG_FHA_1 | 246 | 252 | PF00498 | 0.350 |
LIG_FHA_1 | 4 | 10 | PF00498 | 0.438 |
LIG_FHA_1 | 75 | 81 | PF00498 | 0.425 |
LIG_FHA_2 | 195 | 201 | PF00498 | 0.571 |
LIG_FHA_2 | 257 | 263 | PF00498 | 0.547 |
LIG_LIR_Gen_1 | 101 | 110 | PF02991 | 0.334 |
LIG_LIR_Gen_1 | 6 | 11 | PF02991 | 0.535 |
LIG_LIR_LC3C_4 | 107 | 110 | PF02991 | 0.475 |
LIG_LIR_Nem_3 | 101 | 105 | PF02991 | 0.384 |
LIG_LIR_Nem_3 | 138 | 144 | PF02991 | 0.332 |
LIG_LIR_Nem_3 | 58 | 63 | PF02991 | 0.445 |
LIG_LIR_Nem_3 | 6 | 10 | PF02991 | 0.417 |
LIG_LIR_Nem_3 | 70 | 75 | PF02991 | 0.413 |
LIG_SH2_CRK | 102 | 106 | PF00017 | 0.413 |
LIG_SH2_CRK | 149 | 153 | PF00017 | 0.363 |
LIG_SH2_STAP1 | 119 | 123 | PF00017 | 0.449 |
LIG_SH2_STAT5 | 147 | 150 | PF00017 | 0.366 |
LIG_SH3_3 | 111 | 117 | PF00018 | 0.315 |
LIG_SH3_3 | 165 | 171 | PF00018 | 0.533 |
LIG_SUMO_SIM_anti_2 | 247 | 256 | PF11976 | 0.570 |
LIG_SUMO_SIM_par_1 | 160 | 167 | PF11976 | 0.643 |
LIG_TRAF2_1 | 197 | 200 | PF00917 | 0.534 |
MOD_CDC14_SPxK_1 | 73 | 76 | PF00782 | 0.376 |
MOD_CDK_SPxK_1 | 70 | 76 | PF00069 | 0.376 |
MOD_CK1_1 | 244 | 250 | PF00069 | 0.547 |
MOD_CK1_1 | 270 | 276 | PF00069 | 0.639 |
MOD_CK1_1 | 279 | 285 | PF00069 | 0.684 |
MOD_CK1_1 | 70 | 76 | PF00069 | 0.449 |
MOD_CK2_1 | 122 | 128 | PF00069 | 0.320 |
MOD_CK2_1 | 194 | 200 | PF00069 | 0.540 |
MOD_CK2_1 | 256 | 262 | PF00069 | 0.548 |
MOD_GlcNHglycan | 178 | 181 | PF01048 | 0.610 |
MOD_GlcNHglycan | 219 | 222 | PF01048 | 0.601 |
MOD_GlcNHglycan | 269 | 272 | PF01048 | 0.637 |
MOD_GlcNHglycan | 44 | 47 | PF01048 | 0.558 |
MOD_GSK3_1 | 118 | 125 | PF00069 | 0.418 |
MOD_GSK3_1 | 131 | 138 | PF00069 | 0.414 |
MOD_GSK3_1 | 194 | 201 | PF00069 | 0.545 |
MOD_GSK3_1 | 207 | 214 | PF00069 | 0.600 |
MOD_GSK3_1 | 241 | 248 | PF00069 | 0.607 |
MOD_GSK3_1 | 275 | 282 | PF00069 | 0.676 |
MOD_GSK3_1 | 42 | 49 | PF00069 | 0.551 |
MOD_GSK3_1 | 70 | 77 | PF00069 | 0.361 |
MOD_GSK3_1 | 94 | 101 | PF00069 | 0.359 |
MOD_N-GLC_1 | 164 | 169 | PF02516 | 0.668 |
MOD_NEK2_1 | 122 | 127 | PF00069 | 0.459 |
MOD_NEK2_1 | 136 | 141 | PF00069 | 0.328 |
MOD_NEK2_1 | 75 | 80 | PF00069 | 0.378 |
MOD_PIKK_1 | 67 | 73 | PF00454 | 0.418 |
MOD_PKA_1 | 245 | 251 | PF00069 | 0.350 |
MOD_PKA_2 | 110 | 116 | PF00069 | 0.413 |
MOD_PKA_2 | 12 | 18 | PF00069 | 0.530 |
MOD_PKA_2 | 275 | 281 | PF00069 | 0.754 |
MOD_PKA_2 | 94 | 100 | PF00069 | 0.376 |
MOD_PKB_1 | 274 | 282 | PF00069 | 0.759 |
MOD_Plk_1 | 164 | 170 | PF00069 | 0.463 |
MOD_Plk_1 | 88 | 94 | PF00069 | 0.413 |
MOD_Plk_2-3 | 211 | 217 | PF00069 | 0.400 |
MOD_Plk_4 | 118 | 124 | PF00069 | 0.477 |
MOD_Plk_4 | 131 | 137 | PF00069 | 0.389 |
MOD_Plk_4 | 51 | 57 | PF00069 | 0.410 |
MOD_Plk_4 | 76 | 82 | PF00069 | 0.342 |
MOD_ProDKin_1 | 70 | 76 | PF00069 | 0.376 |
MOD_SUMO_rev_2 | 210 | 220 | PF00179 | 0.410 |
MOD_SUMO_rev_2 | 249 | 259 | PF00179 | 0.495 |
TRG_ENDOCYTIC_2 | 102 | 105 | PF00928 | 0.328 |
TRG_ENDOCYTIC_2 | 119 | 122 | PF00928 | 0.328 |
TRG_ENDOCYTIC_2 | 149 | 152 | PF00928 | 0.357 |
TRG_ENDOCYTIC_2 | 60 | 63 | PF00928 | 0.442 |
TRG_ER_diArg_1 | 274 | 277 | PF00400 | 0.500 |
TRG_Pf-PMV_PEXEL_1 | 196 | 200 | PF00026 | 0.607 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1PE82 | Leptomonas seymouri | 68% | 100% |
A0A0S4JAR9 | Bodo saltans | 36% | 95% |
A0A1X0P8D5 | Trypanosomatidae | 41% | 100% |
A0A3Q8IVT9 | Leishmania donovani | 84% | 100% |
A0A3R7MW02 | Trypanosoma rangeli | 42% | 100% |
A4ICN0 | Leishmania infantum | 84% | 100% |
D0A2T2 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 37% | 100% |
E9ASM4 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 81% | 100% |
Q4Q1X2 | Leishmania major | 83% | 100% |
V5BQE4 | Trypanosoma cruzi | 46% | 100% |